Oxcarbazepine for neuropathic pain

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2017, Pages

  Zhou, Muke ^a   Chen, Ning ^a   He, Li ^a   Yang, Mi ^a   Zhu, Cairong ^b   Wu, Fengbo ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OXCARBAZEPINE; PLACEBO; ANALGESIC AGENT; CARBAMAZEPINE;

ANALGESIA; BACKACHE; BLURRED VISION; DIABETIC NEUROPATHY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; FATIGUE; HEADACHE; HUMAN; META ANALYSIS; METHODOLOGY; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROPATHIC PAIN; PAIN ASSESSMENT; PERIPHERAL NERVE INJURY; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RADICULOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; VOMITING; WEAKNESS; ANALOGS AND DERIVATIVES; NEURALGIA; NUMBERS NEEDED TO TREAT;

ANALGESICS, NON-NARCOTIC; CARBAMAZEPINE; DIABETIC NEUROPATHIES; HUMANS; NEURALGIA; NUMBERS NEEDED TO TREAT; RADICULOPATHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85036666630     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007963.pub3     Document Type: Review

References (80)

1. Multicenter, double-blind, randomized placebo-control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&productid=330 (accessed 2 October 2015). 3439221
2. Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurologica Scandinavica 2006;113(6):395-404. [PUBMED: 16674606]3439219
3. Beydoun A, Wan Y, Hopwood M, Liebel J. Results of a randomized, placebo-controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology 2004;11 Suppl 2:101. 3439220
4. Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&rank=1 2014 (accessed 2 October 2015). 3439224
5. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 2014;155(11):2263-73. [PUBMED: 25139589]4387413
6. Multicenter, double-blind, randomized placebo-control, parallel-group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&productid=330 (accessed 2 October 2015). 3439229
7. Dogra S, Beydoun S, Hopwood M, Mazzola J, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Journal of Pain 2004;5(3 Suppl 1):S6. 3439226
8. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. European Journal of Pain 2005;9(5):543-54. [PUBMED: 16139183]3439228
9. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y, Liebel J. Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo-controlled study. European Journal of Neurology 2004;11 Suppl 2:92. 3439227
10. Multicenter, double-blind, randomized, placebo-control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&productid=330 (accessed 2 October 2015). 3439232
11. Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica 2006;114(3):177-80. [PUBMED: 16911345]3439231
12. Riviere M-E, Wan Y, Hopwood M, Liebel J. Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo-controlled study. European Journal of Neurology 2004;11 Suppl 2:101. 3439233
13. Multicenter, double-blind, randomized, placebo-control, parallel-group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&productid=330 (accessed 2 October 2015). 3439236
14. Harden RN, Urniasz KL, Hopwood M, Wan Y. Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double-blind, randomized, placebo-controlled study. Neurology 2005;64 Suppl 1:A120-1. 3439235
15. Besi E, Boniface DR, Cregg R, Zakrzewska JM. Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). Journal of Headache and Pain 2015;16:563. 7186164
16. Beydoun A, D'Souza J. Oxcarbazepine versus carbamazepine in patients with new onset trigeminal neuralgia result of double blind comparative trial [abstract no.P06.116]. Neurology 2002;58 Suppl 3:A471. 3439238
17. Beydoun S, Alarcón F, Mangat S, Wan Y. Long-term safety and tolerability of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica 2007;115(4):284-8. 3439240
18. Brainer-Lima P, Naylor F. Oxcarbazepine for cancer-related neuropathic pain and opiate detoxification. 22nd Annual Meeting of the American Pain Society; 2003 March 20-23; Chicago (IL). 2003. 3439242
19. Gong JJ. A randomised controlled trial of 3 drugs for the treatment of idiopathic trigeminal neuralgia. Journal of China Traditional Chinese Medicine Information 2010;2(12):74. 3439244
20. Hu YJ. The comparative efficacy of oxcarbazepine and carbamazepine for trigeminal neuralgia. Shandong Medical Journal 2010;50(25):107. 3439246
21. Li G, Zha Q, Chen JZ, Cao QH, Peng WJ. Clinical efficacy of oxcarbazepine for primary trigeminal neuralgia. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine 2011;21(3):167-8. 3439248
22. Liebel J. Results of a double-blind trial comparing oxcarbazepine (OXC) vs carbamazepine (CBZ) in newly diagnosed, untreated patients with trigeminal neuralgia. Journal of the Neurological Sciences 2001;187 Suppl 1:S5. 3439250
23. Lindström P. The analgesic effect of carbamazepine in trigeminal neuralgia. Pain 1987;28 Suppl 4:S85. 3439252
24. Symptom-based treatment for neuropathic pain in spinal cord injured patients, randomized clinical trial, 2014. clinicaltrials.gov/ct2/show/study/NCT02180880?term=oxcarbazepine&rank=34 (accessed 2 October 2015). 7186167
25. Min K, Oh Y, Lee SH, Ryu JS. Symptom-based treatment of neuropathic pain in spinal cord-injured patients: a randomized crossover clinical trial. American Journal of Physical Medicine & Rehabilitation 2016;95(5):330-8. 7186166
26. Rémillard G. Oxcarbazepine and intractable trigeminal neuralgia. Epilepsia 1994;35 Suppl 3:S28-9. 3439257
27. Venancio-Ramirez L, Hernández-Santos JR, Tenopala-Villegas S, Torres-Huerta JC, Rivera-León G, Canseco-Aguilar C. Comparison of oxcarbazepine and gabapentin at standard dose in treatment of pain for postherpetic neuropathy. Revista Mexicana de Anestesiologia 2004;27(3):129-33. 3439259
28. Zhou JF. A clinical research on the pharmacological treatment of trigeminal neuralgia. Medical Information Operations Sciences Fascicule 2010;1:89. 3439261
29. NCT02219373. Gabapentin and oxcarbazepine for chronic neuropathic pain in children and adolescents: a clinical effectiveness study. clinicaltrials.gov/ct2/show/NCT02219373 (accessed 15 January 2017). 4387415
30. Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology 2006;13(11):1153-69.
31. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. European Journal of Neurology 2010;17(9):1113-e88. [DOI: 10.1111/j.1468-1311.2010.02999.x]
32. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized placebo-controlled clinical trials. Clinical Therapeutics 2003;25(1):81-104.
33. Beydoun A, Schmidt D, Souza J. Oxcarbazepine versus carbamazepine in trigeminal neuralgia: a meta-analysis of three double-blind comparative trials. Neurology 2002;58 Suppl 3:A131.
34. Beydoun A, Schmidt D, D'Souza J, on behalf of the oxcarbazepine study group. Meta-analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. 21st American Pain Society Annual Meeting; 2002 Mar 14-17; Baltimore (MD).
35. Bieri D, Reeve RA, Champion GD, Addicoat L, Ziegler JB. The Faces Pain Scale for the self-assessment of the severity of pain experienced by children: development, initial validation and preliminary investigation for ratio scale properties. Pain 1990;41(2):139-50.
36. Birse F, Derry S, Moore RA. Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009485.pub2]
37. Callin S, Bennett MI. Assessment of neuropathic pain. Continuing Education in Anaesthesia, Critical Care and Pain 2008;8(6):210-3.
38. Carpenter KJ, Dickenson AH. Molecular aspects of pain research. Pharmacogenomics Journal 2002;2(2):87-95.
39. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. Journal of Pain and Symptom Management 2003;25(5 Suppl):S31-5.
40. Corrigan R, Derry S, Wiffen PJ, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009486.pub2]
41. Criscuolo S, Auletta C, Lippi S, Brogi F, Brogi A. Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. Acta Neurologica Scandinavica 2005;111(4):229-32.
42. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen L. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Research 1989;3(1):70-6.
43. Davis MP, Walsh D. Epidemiology of cancer pain and factors influencing poor pain control. American Journal of Hospice and Palliative Care 2004;21(2):137-42.
44. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
45. Di Stefano G, La Cesa S, Truini A, Cruccu G. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. Journal of Headache and Pain 2014;15:34.
46. Dickenson AH, Matthews EA, Suzuki R. Neurobiology of neuropathic pain: mode of action of anticonvulsants. European Journal of Pain 2002;6 Suppl A:51-60.
47. Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 2007;67(9):1265-89.
48. Finnerup NB, Sindrup SH, Jensen TS. Chronic neuropathic pain: mechanisms, drug targets and measurement. Fundamental Clinical Pharmacology 2007;21(1):129-36.
49. Foley KM. Opioids and chronic neuropathic pain. New England Journal of Medicine 2003;348(13):1279-81.
50. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009183.pub2]
51. GRADE Working Group, McMaster University. GRADEpro. Version 3.2 for Windows. Hamilton (ON): GRADE Working Group, McMaster University, 2008.
52. Heliovaara M, Impivaara O, Sievers K, Melkas T, Knekt P, Korpi J, et al. Lumbar disc syndrome in Finland. Journal of Epidemiology and Community Health 1987;41(3):251-8.
53. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
54. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
55. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
56. Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J. Human leukocyte antigen-associated drug hypersensitivity. Current Opinion in Immunology 2013;25(1):81-9.
57. Jensen TS, Gottrup H, Sindrup SH. The clinical picture of neuropathic pain. European Journal of Pharmacology 2001;429(1-3):1-11.
58. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. European Journal of Pain 2002;6 Suppl A:61-8.
59. Lindstrom P. The analgesic effect of carbamazepine in trigeminal neuralgia. Pain 1987;30:S85.
60. Magenta P, Arghetti S, Di Palma F, Jann S, Sterlicchio M, Bianconi C, et al. Oxcarbazepine is effective and safe in the treatment of neuropathic pain: pooled analysis of seven clinical studies. Neurological Sciences 2005;26(4):218-26.
61. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd Edition. Seattle (WA): IASP Press, 1994.
62. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2]
63. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3]
64. Nasreddine W, Beydoun A. Oxcarbazepine in neuropathic pain. Expert Opinion on Investigational Drugs 2007;16(10):1615-25.
65. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
66. Ryan R, Hill S, Cochrane Consumers and Communication Group. How to GRADE the quality of the evidence, Version 1.0, June 2016. cccrg.cochrane.org/author-resources (accessed prior to 16 November 2017).
67. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clinical Journal of Pain 2002;18(6):350-4.
68. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
69. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
70. Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing trends. Trends in Pharmacological Sciences 2004;25(12):613-7.
71. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630-5.
72. Verma S, Estanislao L, Simpson D. HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs 2005;19(4):325-34.
73. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
74. Werhagen L, Budh CN, Hultling C, Molander C. Neuropathic pain after traumatic spinal cord injury? Relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord 2004;42(12):665-73.
75. Wiffen PJ, McQuay HJ, Edwards J, Moore RA. WITHDRAWN: Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD001133.pub3]
76. Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD006044.pub4]
77. Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD005451.pub3]
78. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. Journal of Clinical Nursing 2005;14(7):798-804.
79. Zhou M, He L, Yang M, Chen N, Guo J, Li Q, Yang X, Yang J, Zhu C. Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007963]
80. Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD007963.pub2]